FLT1 and glioma: In the Vac + Bev group, the chi-squared test was used to compare categorical variables (type of vaccination, VEGFRs vs. VEGFRs with multiple glioma oncoantigens; timing of Bev administration, ≥110 days vs. <110 days after the last vaccination; number of vaccinations, ≥10 vs. <10; CTL induction of VEGFR1 or VEGFR2, positive vs. negative).